*** Media Alert *** - Survey of Health Care Providers and People Living with Relapsing Multiple Sclerosis Reveals Unmet Treatmen
Posted Nov 17 2009 10:20pm
The National Multiple Sclerosis (MS) Society, in collaboration with EMD Serono, announced a poster presentation, “MS Viewpoints: Outlook on Emerging MS Therapies,” at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The MS Viewpoints survey was conducted to evaluate the perceptions of health care professionals and people living with relapsing MS.
Key findings presented in the poster at ECTRIMS include: · 41% of people living with relapsing MS reported feeling anxious about needles or intravenous therapy · Nearly 20% of people with relapsing MS reported delaying prescribed therapy. Of those who delayed therapy, 29% did not start treatment for more than 1 year · 68% of neurologists believed patients would initiate therapy sooner if an oral medication were available
Current treatment recommendations indicate that treatment should be started immediately following definitive diagnosis.1,2 Oral administration of MS treatments, MS Viewpoints found, is a desired improvement to MS therapy.